子宫内膜癌术前放疗对Bcl-2,bax表达的影响

目的探讨Bcl-2，bax与子宫内膜癌的相关性及术前放疗对其表达影响。方法从2002年10月-2006年10月在我科住院的子宫内膜癌患者中筛选符合纳入标准的病例50倒。取其刮宫内膜癌组织标本、放疗且术后内膜癌标本。分为放疗前组、放疗后组，采用免疫组织化学方法检测Bcl-2，bax的表达，并观察表达的变化。结果BcL-2表达放疗后（64．0％）较放疗前（82．0％）减弱，差异有显著性（P〈0．01）；bax蛋白表达放疗后（76．0％）较放疗前（62．0％）增强，差异有显著性（P〈0．01），结论①子宫内膜癌的发生过程中与癌基因及抑癌基因Bcl-2,bax有密切的关系。②子宫内膜癌患者放疗前后癌组织中Bcl-2，bax表达水平发生了明显的改变，放射治疗可能是通过诱导细胞凋亡起到抗肿瘤作用的。③子宫内膜癌为放射敏感性肿瘤。     

超声热疗临床应用的研究

目的：通过超声热疗配合常规放疗治疗晚期恶性肿瘤的临床研究，评价超声热疗的疗效及与疗效有关的加热参数。材料和方法： 对１７ 例晚期恶性肿瘤的１７ 个病灶用常规放疗加超声热疗。放疗用直线加速器外照射，每次２ Ｇｙ、周５ 次， 总剂量４０～７０ Ｇｙ。热疗在放疗后３０ ｍ ｉｎ 内进行，每周加热１～２ 次，每次加温时间 ６０ ｍ ｉｎ，６～８ 次一疗程。全例病人每次加温时实测肿瘤内温度。结果：在可评价的１３例中，ＣＲ ２３．１％ （３／１３）、ＰＲ ４６．２％ （６／１３）、ＮＣ ２３．１％ （３／１３）、ＰＤ ７．７％ （ １／１３） ， 有效率（ＣＲ＋ ＰＲ）为６９．３％ 。肿瘤中心部温度达到４２．５℃以上的累积时间和总加热次数是决定疗效的重要参数。在１７ 例患者的 ８９ 次加温中，副作用的发生率相对较低。结论：使用超声热疗配合放疗，只要实现满负荷加温，进一步提高肿瘤的局部控制率是完全可能的     

52例肺癌患者放疗前肺功能和放疗疗效关系分析

为了探讨放疗前肺功能与放疗疗效的关系，作者于１９８７年１月至１９９０年１２月对５２例无急、慢性呼吸衰竭的肺癌患者在放疗前做了肺功能检测和血气分析，结果表明，放疗前肺功能不能反映肿瘤乏氧程度，也不能作为肿瘤对放疗敏感性的指标，只有直接测量肿瘤原发灶内的乏氧程度才能了解肿瘤对放疗的敏感性，预测放疗的疗效。     

Bromodeoxyuridine Labeling Index as an Indicator of Early Tumor Response to Preoperative Radiotherapy in Patients with Rectal Cancer

Purpose Assessment of tumor proliferation rate using Bromodeoxyuridine labeling index (BrdUrdLI) as a possible predictor of rectal cancer response to preoperative radiotherapy (RT). Methods and material Ninety-two patients were qualified either to short RT (5 Gy/fraction/5 days) and surgery about 1 week after RT (schedule I), or to short RT and 4–5 weeks interval before surgery (schedule II). Tumor samples were taken twice from each patient: before RT and at the time of surgery. The samples were incubated with BrdUrd for 1 h at 37°C, and the BrdUrdLI was calculated as a percentage of BrdUrd-labeled cells. Results Thirty-eight patients were treated according to schedule I and 54 patients according to schedule II. Mean BrdUrdLI before RT was 8.5% and its value did not differ between the patients in the two compared groups. After RT tumors showed statistically significant growth inhibition (reduction of BrdUrdLI). As the pretreatment BrdUrd LI was not predictive for early clinical and pathologic tumor response, prognostic role of the ratio of BrdUrdLI after to BrdUrdLI before RT was considered. The ratios were calculated separately for fast (BrdUrd LI > 8.5%) and slowly (BrdUrd LI ≤ 8.5%) proliferating tumors and correlated with overall treatment time (OTT, i.e., time from the first day of RT to surgery). One month after RT, accelerated proliferation was observed only in slowly proliferating tumors. Conclusions Pretreatment BrdUrdLI was not predictive for early clinical and pathologic tumor response. The ratio after/before RT BrdUrdLI was correlated to inhibition of proliferation in responsive tumors. The paper was presented at ECCO 13, October 30 to November 03, 2005 in Paris, France     

Dosimetric Characteristics of the Siemens IGRT Carbon Fiber Tabletop

In this work, the dosimetric characteristics of a new commercial carbon fiber treatment table are investigated. The photon beam attenuation properties of the Siemens image-guided radiation therapy (IGRT) tabletop were studied in detail. Two sets of dosimetric measurements were performed. In the first experiment a polystyrene slab phantom was used: the central axis attenuation and the skin-sparing detriment were investigated. In the second experiment, the off-axis treatment table transmission was investigated using a polystyrene cylindrical phantom. Measurements were taken at the isocenter for a 360° rotation of the radiation beam. Our results show that the photon beam attenuation of the Siemens IGRT carbon fiber tabletop varies from a minimum of 2.1% (central axis) to a maximum of 4.6% (120° and 240° beam incidence). The beam entrance dose increases from 82% to 97% of the dose at the depth of maximum for a clinical 6-MV radiation field. The depth of maximum also decreases by 0.4 cm. Despite the wedge cross section of the table the beam attenuation properties of the IGRT tabletop remain constant along the longitudinal direction. American Association of Medical Dosimetrists.     

鼻咽癌放疗后咽部菌群的变化

目的:了解鼻咽癌放疗后患者咽部菌群的变化,为临床防治继发感染提供实验依据。方法:32例鼻咽癌放疗患者,于放疗前后分别在照射区域粘膜采集唾液标本,进行细菌的分离培养鉴定,测量可培养细菌的检出率、检出量和构成比。结果:与放疗前相比,放疗后照射区域的链球菌属、葡萄球菌属、白色念珠菌和绿脓杆菌检出增加;而放线菌属和奈瑟菌属检出减少(P<0.05)。结论:鼻咽癌放疗可影响咽部的微生态平衡,是导致鼻咽癌放疗后患者发生感染的重要原因之一。     

颅内生殖细胞瘤综合治疗

报告５０例颅内生殖细胞瘤，手术治疗１９例，放射治疗４３例。综合治疗后临床症状改善４１例，无效２例。随访３２例，其中恢复正常工作或学习者１４例，生活能自理１２例，生活部分需人帮助４例，死亡２例。５年生存率为５０％。推荐放疗为首选治疗手段，并对合并颅内压增高及多发性、复发性肿瘤的治疗作了讨论。     

放疗同期卡莫氟化疗治疗局部中晚期鼻咽癌的Ⅲ期临床观察

目的:探讨患者对联合应用诱导化疗和放疗同期口服卡莫氟治疗局部中晚期鼻咽癌疗效和不良反应.方法:收治66例局部中晚期鼻咽癌患者,随机分为两组,诱导化疗随后放疗组简称为对照纽,诱导化疗随后放疗同期卡莫氟治疗组简称为治疗组.两组患者数均为33例.进行根治性放疗前两组患者均接受两个疗程诱导化疗.治疗组在放疗期间同时口服卡莫氟.结果:诱导化疗有效率高,平均有效率高达87%,其中平均完全缓解率(CR)为8.7%、不完全缓解率(PR)为78.4%.对照组鼻咽肿瘤、颈部转移淋巴结全消平均剂量均高于治疗组,统计学有差异.放疗后3个月治疗组鼻咽、颈部转移淋巴结CR均高于对照组(p=0.016,P=0.042).随访期内治疗组患者局部复发率和远处转移率有降低趋势.临床治疗中出现的主要毒副反应为白细胞下降、口腔粘膜炎、急性放射性皮炎及由卡莫氟引起的热感、尿频、头昏等.结论:放疗同期口服卡莫氟治疗局部中晚期鼻咽癌,降低了鼻咽和颈部肿瘤完全消退的照射剂量,提高了鼻咽肿瘤和颈部转移灶的完全缓解率,局部复发率和远处转移率有下降趋势.尽管加卡莫氟患者毒的副作用加重,但可以耐受,经对症处理绝大部分患者能按计划完成治疗.在鼻咽癌同步化放疗方案中卡莫氟的推荐剂量为600mg/d,分3次口服.放疗同期口服卡莫氟治疗的远期疗效有待于进一步观察.     

颌面颈部恶性淋巴瘤临床分析

目的：总结口腔颌面颈部恶性淋巴瘤(ML)的诊断方法及治疗措施。方法：回顾性分析收治的ML患者38例的临床资料。结果：霍奇金病(HD)5例，非霍奇金淋巴瘤(NHL)33例，31例采用综合治疗，7例采用单纯化疗，38例1，3，5a生存者分别为5，14，12例，存活患者中以临床Ⅰ，Ⅱ期者占绝大多数，死亡患者中以Ⅳ期为多。结论：早期明确ML的诊断并早期治疗效果较好，综合治疗是最有效的治疗手段，临床分期对预后有重要参考价值。